At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 120 enrolled
Drug / intervention
alteplasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multicenter, Single-arm Trial to Assess Safety and Efficacy of Alteplase (Rt-PA) in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
In Brief
A Phase 3 clinical trial evaluating alteplase for Stroke. Completed, enrolled 120 participants across 11 sites.
Detailed Summary
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartNov 2016
Primary CompletionDec 2017
TodayJul 2026
First PostedOct 12, 2016
Enrollment StartNov 15, 2016
Primary CompletionDec 11, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.7 years ago
Interventions
alteplasedrug